An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.7476-7477
Main Authors: Stein, Anthony S., Bajel, Ashish, Fleming, Shaun, Jongen-Lavrencic, Mojca, Garciaz, Sylvain, Maiti, Abhishek, Boissel, Nicolas, De Botton, Stephane, Huls, Gerwin A., de Leeuw, David C., Avigan, David, Jensen, Kyle, Demers, Brigitte, Wagenaar, Timothy, Mi, Gu, Ziti-Ljajic, Samira, Draganov, Dobrin, Abbadessa, Giovanni, Wei, Andrew H
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-166000